NSRX (Nasus Pharma) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSRX Nasus Pharma Ltd NSRX
14 GF Score
Price $2.91
! 4 Warning Signs
View Full Analysis

What is Nasus Pharma ROCE %?

Nasus Pharma NSRX -3.96% 14 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nasus Pharma's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Nasus Pharma  (AMEX:NSRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nasus Pharma ROCE % Related Terms

Nasus Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Nasus Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nasus Pharma ROCE % Chart

Nasus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 0.00 0.00 0.00

Nasus Pharma Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSRX
14GF Score
Nasus Pharma Ltd NSRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nasus Pharma ROCE % Calculation

Nasus Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4.904/( ( (0.717 - 3.929) + (5.004 - 2.163) )/ 2 )
=-4.904/( (-3.212+2.841)/ 2 )
=-4.904/-0.1855
=2,643.67 %

Nasus Pharma's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-7.42/( ( (0.639 - 4.953) + (5.004 - 2.163) )/ 2 )
=-7.42/( ( -4.314 + 2.841 )/ 2 )
=-7.42/-0.7365
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Nasus Pharma (NSRX) has a ROCE % of 0.00% as of Dec. 2025.
Is Nasus Pharma's ROCE % too high?
Nasus Pharma's current ROCE % is 0.00%. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's ROCE % compare to MIRA and SCLX?
Nasus Pharma's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasus Pharma's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nasus Pharma Business Description

Address Yigal Alon 65, Tel Aviv, ISR, 6744317
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score

Get the complete analysis for NSRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price